Immunic Inc [IMUX] stock is trading at $0.76, up 5.20%. An important factor to consider is whether the stock is rising or falling in short-term value. The IMUX shares have gain 9.29% over the last week, with a monthly amount drifted -1.29%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on November 25, 2024, and set its price target to $10. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $6 on August 27, 2024. SVB Leerink downgraded its rating to a Mkt Perform but $5 remained the price target by the analyst firm on October 21, 2022. In a note dated April 15, 2021, Aegis Capital initiated an Buy rating and provided a target price of $55 on this stock.
Immunic Inc [IMUX] stock has fluctuated between $0.56 and $2.11 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Immunic Inc [NASDAQ: IMUX] shares were valued at $0.76 at the most recent close of the market. An investor can expect a potential return of 557.89% based on the average IMUX price forecast.
Analyzing the IMUX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -4.7, Equity is -3.27 and Total Capital is 19.89. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7400 points at the first support level, and at 0.7149 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7841, and for the 2nd resistance point, it is at 0.8031.
Ratios To Look Out For
For context, Immunic Inc’s Current Ratio is 0.74. On the other hand, the Quick Ratio is 0.74, and the Cash Ratio is 0.56.
Transactions by insiders
Recent insider trading involved Nash Duane, Executive Chairman, that happened on Jun 13 ’25 when 20000.0 shares were purchased. President and COO, Tardio Jason completed a deal on Jun 05 ’25 to buy 12512.0 shares. Meanwhile, CEO and Director Vitt Daniel bought 15000.0 shares on Jun 04 ’25.
